Context Therapeutics Inc. (6K9.F)
| Previous Close | 1.8164 |
| Open | 1.8544 |
| Bid | 1.8504 x N/A |
| Ask | 1.9076 x N/A |
| Day's Range | 1.8544 - 1.8544 |
| 52 Week Range | 1.2050 - 8.9860 |
| Volume | |
| Avg. Volume | 143 |
| Market Cap | 30.541M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.8350 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- CNW Group
Context Therapeutics and The Menarini Group Announce Clinical Trial Collaboration and Supply Agreement to Evaluate ONA-XR and Elacestrant Combination
Context Therapeutics Inc. ("Context" or the "Company") (Nasdaq: CNTX), a women's oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, and The Menarini Group ("Menarini") today announced a clinical trial collaboration and supply agreement for Menarini's oral selective estrogen receptor degrader (SERD), elacestrant.
- Simply Wall St.
Is Context Therapeutics (NASDAQ:CNTX) In A Good Position To Deliver On Growth Plans?
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
- GlobeNewswire
Context Therapeutics® Reports First Quarter 2022 Operating and Financial Results
Abstract on results of the monotherapy portion of Phase 2 ONA-XR clinical trial in granulosa cell tumors of the ovary accepted for oral presentation at the 2022 ASCO Annual Meeting Preclinical data presented at AACR Annual Meeting showcased potential of ONA-XR and CLDN6xCD3 bispecific development program PHILADELPHIA, May 11, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treat
